title: Everolimus dual effects of an area vasculosa angiogenesis and lymphangiogenesis.
abstract: Recently approved as treatment for astrocytoma, kidney and pancreatic cancer, everolimus acts on tumor cells by inhibiting tumor cell growth and proliferation, as well as by inhibition of angiogenic activity by both direct effects on vascular cell proliferation and indirect effects on growth factor production. The effects of everolimus on early stages of normal vasculogenesis, angiogenesis and lymphangiogenesis are not yet available. We found increased development of intravascular pillars by using area vasculosa of the chick chorioallantoic membrane treated with everolimus. An active lymphangiogenic response was highlighted by the expression of Prospero homeobox protein 1 (Prox1) and podoplanin, together with vascular endothelial growth factor receptor C (Vegf-C) and vascular endothelial growth factor receptor 3 (Vegfr-3) expression on day 4 in the treated group. These findings suggest a potential role of everolimus in the activation of lymphangiogenesis.
authors.affiliation: "Victor Babeş" University of Medicine and Pharmacy, Department of Histology, Angiogenesis Research Center Timisoara, Piata Eftimie Murgu nr. 2, 300041, Timisoara, Timis, Romania. ancacimpean1972@yahoo.com
authors.forename: Raluca Amalia
authors.initials: RA
authors.lastname: Ceausu
authors.forename: Anca Maria
authors.initials: AM
authors.lastname: Cimpean
authors.forename: Ivanka
authors.initials: I
authors.lastname: Dimova
authors.forename: Ruslan
authors.initials: R
authors.lastname: Hlushchuk
authors.forename: Valentin
authors.initials: V
authors.lastname: Djonov
authors.forename: Puşa Nela
authors.initials: PN
authors.lastname: Gaje
authors.forename: Marius
authors.initials: M
authors.lastname: Raica
mesh_terms: D000818:Animals; D030161:Avian Proteins / Q000378:metabolism; D002642:Chick Embryo; D049033:Chorioallantoic Membrane / Q000098:blood supply* / Q000378:metabolism; D000068338:Everolimus; D018398:Homeodomain Proteins / Q000378:metabolism; D007150:Immunohistochemistry; D007166:Immunosuppressive Agents / Q000494:pharmacology; D042583:Lymphangiogenesis / Q000187:drug effects*; D008562:Membrane Glycoproteins / Q000378:metabolism; D009088:Mucoproteins / Q000378:metabolism; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000494:pharmacology; D013997:Time Factors; D025521:Tumor Suppressor Proteins / Q000378:metabolism; D042582:Vascular Endothelial Growth Factor C / Q000378:metabolism; D040321:Vascular Endothelial Growth Factor Receptor-3 / Q000378:metabolism; D000098551:Prospero-Related Homeobox 1 Protein
chemical_list: D030161:Avian Proteins; D018398:Homeodomain Proteins; D007166:Immunosuppressive Agents; D008562:Membrane Glycoproteins; D009088:Mucoproteins; D025521:Tumor Suppressor Proteins; D042582:Vascular Endothelial Growth Factor C; D000098551:Prospero-Related Homeobox 1 Protein; D000068338:Everolimus; D040321:Vascular Endothelial Growth Factor Receptor-3; D020123:Sirolimus